The specialists

After ten years of successful development, MorphoSys launched tafasitamab, its first proprietary compound for the treatment of patients with a specific type of lymphoma – and as a fully integrated biopharmaceutical company is now playing a leading role in a key area of medicine. In our reporting, we accompany the company on this journey, which has one major goal: to cure cancer and autoimmune diseases with antibody-based therapeutics. This is the impact people at MorphoSys work for every day.